Our Process and Advisory Committee
Our Process
The George Shultz Innovation Fund invests in promising startups from an ecosystem that includes the University of Chicago, Argonne National Laboratory, Fermilab, and the Marine Biological Laboratory. The core mission of the George Shultz Innovation Fund is to help researchers turn their innovations into ventures that advance cutting-edge technologies, generate significant financial returns, and create lasting impact for humankind.
This mission is accomplished in two ways.
- Investing in startups created by faculty, students, and staff in order to help them bridge the gap between basic research funding and commercial investment.
- Surrounding these startups with a community of support – including distinguished angel and venture capital investors, scientists, and entrepreneurs – to help move their projects forward.
INVESTMENT PROCESS
Our investment process resembles that of a traditional venture capital fund, and is run once a year in the Spring quarter. After evaluating applications, we select finalists to advance to due diligence, a rigorous 10-week process spearheaded by our Innovation Fund Associates. We then make an investment decision for each venture based on the outcome of due diligence and the input of our Advisory Committee, and ultimately select ventures for investment.
What finalists receive
- 10-weeks of rigorous, venture-capital-style due diligence. A multi-disciplinary team of Innovation Fund Associates spends 500+ hours analyzing your business from an investor’s perspective, helping prepare you to raise additional capital.
- Up to $250,000 of seed funding (if selected).
What to expect
BEFORE
Successful applicants to share three characteristics:
- Committed team with dedicated technology and business founders
- Significant technical milestones achieved, including proof of concept
- Value proposition of technology validated with end customers
DURING
Our diligence process is conducted by Innovation Fund Associates, multi-disciplinary teams of students, over the 10-week cycle. Startup teams will commit 1-2 hours/week to the diligence process, consisting of meetings with the Innovation Fund Associates, providing materials for due diligence, and/or meeting with the program team. Each investment cycle culminates in a Finals event during which finalists will present to the Advisory Committee.
AFTER
George Shultz Innovation Fund investees receive more than money. They will also receive:
- A SAFE investment up to $250,000
- Year-round support from the Innovation Fund team, including introductions to other investors
- Access to Polsky Center resources and network
Advisory Committee
Robert Altman, MBA ’88, PhD
Member of the Board of Directors, Toltec Pharmaceuticals
Ken Bradley
President and CEO, PixelEXX Systems, Inc.
Paul Burton
Managing Partners, 2Flow Ventures
Mus Chagal, MBA ’97
Executive Chair, Great Lakes Crystal Technologies; Entrepreneur-in-Residence, Polsky Center
Mira Chaurushiya, PhD
Senior Partner, Westlake BioPartners
Coleman Collins
Product, Design, and Strategy, IonQ
Jay Cui, PhD, MBA ’15
Principal, Abingworth
Keith Evans, PhD
President and CEO, Great Lakes Crystal Technologies
Douglass Given, MD, PhD
CEO, Health2047; Managing Partner, G5 Partners
Noel Goodard, PhD
CEO, Qunnect
Steve Gould, MD
Founder and Principal, The Gould Consulting Group
Frank Greco
Executive IT Architect, AI and Machine Learning, IBM
Alexis Ji, PhD, MBA
Partner, Illumina Ventures
Karen Kerr
General Partner, Exposition Ventures
Ania Labno, PhD
Operating Executive, KKR
Steven Lehmann
Director of Venture Operations, Portal Innovations
Scott Meadow, MBA
Clinical Professor of Entrepreneurship, Chicago Booth School of Business
Bela Mehta, MBA
Managing Partner, CITG Capital
Alex Munns, MBA
Assistant Portfolio Manager, Driehaus Capital Management
Armando Pauker, MBA
Managing Director and Co-founder, Tensility Venture Partners
Charles Polsky, MD ’96
Vice President and Director, William Harris Investors
Corey Ritter
Partner, ARCH Venture Partners
Maryam Saleh
Executive Director, Ed Kaplan Family Institute for Innovation and Tech Entrepreneurship
Corsee Sanders, PhD
Board Director, Ultragenyx Pharmaceutical, Inc.
Martin Sanders, MD
Life Sciences Entrepreneur
Lee Shapiro, JD ’80
Managing Partner, 7wire Ventures; CFO, Livongo
David Steinberg, MBA ’01
General Partner, Longwood Fund
Manny Stockman, PhD
Partner, Osage University Partners
Nancy Sullivan
CEO and Managing Director, Illinois Ventures
Brian Tolliver, MBA
Founder and Principal, Triple Edge Consulting
Scott Walbrun, MBA ’19
Principal, BMW iVentures
Diana West-Szymanski
Principal Director of Operations, Plaisance Capital Management